AbbVie Continues To Chase Gilead With New HCV Data
This article was originally published in Scrip
Executive Summary
AbbVie Inc.'s once-daily, ribavirin (RBV)-free, pan-genotypic regimen, ABT-493/ABT-530, achieved impressive results in a Phase II study of genotype 2/3 hepatitis C patients, but it still might not be enough to dethrone current market leader Gilead Sciences.
You may also be interested in...
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.
Podcast: NodThera On The Role Of The Brain In Driving Chronic Disease
Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity.
Deals Of The Year 2023 Winners Revealed
For In Vivo's 16th annual Deals of the Year contest, we selected 12 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.